mtm laboratories Announces the European Launch of CINtec(R) PLUS - Gilde Healthcare

mtm laboratories Announces the European Launch of CINtec(R) PLUS

March 8, 2010

Powerful new biomarker combination for cervical cancer screening 

mtm laboratories, a privately held diagnostics company today announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.*

CINtec® PLUS combines the p16 biomarker, widely validated for diagnostic purposes, with the proliferation marker Ki-67. By combining these two markers in a single diagnostic test, CINtec® PLUS provides both high sensitivity and high specificity for detecting high-grade cervical disease. The performance of this test for highly accurate detection of pre-cancerous cervical lesions has been demonstrated in three clinical trials conducted in over 30,000 women across Europe. In these studies, CINtec® PLUS was demonstrated to have significant clinical utility across a wide range of applications in cervical cancer screening and management.

“The combination of both high sensitivity and specificity in a single test is what sets CINtec® PLUS apart from currently available diagnostic tests”

said Robert Silverman, CEO of mtm laboratories,

“What this means for patients and clinicians is that early stage disease can be identified accurately in time for effective medical intervention. In comparison to the currently available technologies, CINtec® PLUS will minimize over or under diagnosis.”

CINtec® PLUS is the newest in a line of diagnostic and screening tests using the p16 biomarker that have been developed by mtm laboratories. CINtec® Histology and CINtec® Cytology are already marketed in Europe and were launched in 2007.
 
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with headquarters in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com

More news

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
October 17, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025